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Abstract
To prevent important infectious diseases such as tuberculosis, malaria and HIV, vaccines inducing greater T cell responses
are required. In this study, we investigated whether fusion of the M. tuberculosis antigen 85A to recently described adjuvant
IMX313, a hybrid avian C4bp oligomerization domain, could increase T cell responses in pre-clinical vaccine model species.
In mice, the fused antigen 85A showed consistent increases in CD4
+ and CD8
+ T cell responses after DNA and MVA
vaccination. In rhesus macaques, higher IFN-c responses were observed in animals vaccinated with MVA-Ag85A IMX313
after both primary and secondary immunizations. In both animal models, fusion to IMX313 induced a quantitative
enhancement in the response without altering its quality: multifunctional cytokines were uniformly increased and
differentiation into effector and memory T cell subsets was augmented rather than skewed. An extensive in vivo
characterization suggests that IMX313 improves the initiation of immune responses as an increase in antigen 85A specific
cells was observed as early as day 3 after vaccination. This report demonstrates that antigen multimerization using IMX313
is a simple and effective cross-species method to improve vaccine immunogenicity with potentially broad applicability.
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Introduction
A major challenge in vaccinology is the development of effective
vaccines against intracellular pathogens where cell mediated
immunity plays an important protective role. Viral vectored
vaccines have a remarkable capacity to induce and boost antigen-
specific T cells [1], but higher frequency responses will likely be
required to achieve useful protective efficacy [2]. There is,
therefore, a need for adjuvants in the next generation of vectored
vaccines to increase T cell immunogenicity.
Oligomerization is employed by many natural proteins to
increase protein valency, binding affinity and structural stability
[3], and while a pentameric coiled coil was initially used to
improve B-cell responses in mice [4] its sequence is too similar to
its human ortholog to be considered safe for use in humans.
Recently, a series of homologous oligomerization protein domains
were shown to act as adjuvants in mice, resulting in an
augmentation of both B and T cell responses [5,6]. These proteins
were derived from the domain encoded by the last exon of the
complement 4 binding protein (C4bp) a-chain. This exon encodes
the only domain not involved in the complement related functions
of C4bp and is both essential and sufficient for oligomerization of
the seven C4bp alpha chains [7]# and a number of other proteins
[8,9,10,11,12]. Fusion of recombinant Plasmodium yoelii MSP-119
protein to C4bp oligomerization domains from a variety of
mammalian and avian species was shown to improve antibody
responses to this weak immunogen [6]; of the domains tested, a
chicken C4bp hybrid with less than 20% homology to human
C4bp, called IMX313, was shown to induce the highest titers of
MSP-119 specific antibodies, buts its effect on T cell responses was
not investigated.
Tuberculosis (TB) remains one of the most serious worldwide
infections despite the use of the M. bovis strain Bacillus Calmette-
Gue ´rin (BCG) as a vaccine since the 1920s. The most advanced
sub-unit vaccine in clinical development is a modified vaccinia
virus Ankara (MVA) expressing the M. tuberculosis protein 85A.
Clinical trials in both the UK and Africa have shown the
substantial capacity of MVA-Ag85A to boost T cell responses to
BCG in healthy individuals [13,14,15], whether this capacity is
maintained in HIV-infected individuals is unclear. Although there
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33555is currently no clear correlate of protection, T cells have been
shown to play an important role [16,17,18] and therefore
strategies to increase the level of vaccine induced T cells could
have a substantial impact.
In this study we have assessed whether fusion to the IMX313
domain could enhance the T cell mediated response to the M.
tuberculosis antigen 85A in two pre-clinical animal species, mice and
rhesus macaques. In both animal models, IFN-c ELISpot and
multi-parameter flow cytometry were used to investigate the effects
of fusion to IMX313 on the overall quality of the immune response
in terms of cytokine secretion and generation of effector or
memory T cell subsets. Fusion of antigens to the IMX313 domain
is a straightforward method and its ability to enhance T cell
immune responses could have broad applicability across a variety
of animal species and disease settings. In the first instance, we
intend to undertake a direct comparison in humans of MVA-
Ag85A with MVA-Ag85A IMX313 to confirm the results
described here in two very distinct animal species.
Results
Fusion to IMX313 multimerizes antigen 85A
To confirm that fusion of IMX313 resulted in formation of
disulphide-linked multimers without affecting protein expression,
cell lysates from MVA infected BHK cells were analyzed by
Western blots of reducing and non-reducing SDS-PAGE gels
(Figure 1). Under reducing conditions, both Ag85A and Ag85A
IMX313 proteins migrated at the expected apparent molecular
weight of the mature monomeric peptide (35.5 kDa for Ag85A or
40.4 kDa for Ag85A IMX313) (Figure 1d). For both proteins, an
additional higher molecular weight band (,45 kDa for Ag85A
and ,50 kDa for Ag85A IMX313) was observed, probably
representing a glycosylated species, since a predicted N-linked
glycosylation site (NNT) is present within Ag85A (http://www.cbs.
dtu.dk/services/NetNGlyc/), though this conclusion has not been
experimentally verified. More importantly, when the reducing
agent was omitted (Figure 1b and 1c), the Ag85A IMX313 fusion
protein migrated exclusively in excess of ,200 kDa, consistent
with formation of the predicted heptamers (248 kDa). Although
other higher-order species were observed, these results indicate
that the IMX313 domain was functioning as expected to induce
antigen multimerization.
Fusion of antigen 85A to IMX313 enhances CD4
+ and
CD8
+ T cell responses in mice
Initial screening experiments were performed in mice to assess
the ability of IMX313 to enhance antigen 85A-specific responses.
Balb/c mice received two intramuscular (i.m.) immunizations with
either 50 mg of DNA-Ag85A or DNA-Ag85A-IMX313 two weeks
apart and the immune response to Ag85A measured in the blood
or spleen by IFN-c ELISpot. Following a single immunization of
50 mg DNA plasmid vaccine, significant increases in the response
to the dominant CD4
+ (p15) and CD8
+ (p11) T cell epitopes were
observed in PBMCs from mice vaccinated with the Ag85A
IMX313 compared to Ag85A vaccinated controls (Figure 2A).
These increases were enhanced after a second homologous DNA
immunization (Figure 2A) and a significant increase in the p11-
specific response was observed in ex vivo splenocytes two weeks
after the final vaccination (Figure 2B) (2.1-fold increase). A small
1.5-fold increase in the ex vivo p15 response was also detected but
did not reach statistical significance (Figure 2B).
For the assessment of IMX313 in an MVA vector, Balb/c mice
were vaccinated intramuscularly (i.m.) or intradermally (i.d.) with
10
6 PFU of either MVA-Ag85A or MVA-Ag85A IMX313 and
the immune responses measured in the spleen of mice by IFN-c
ELISpot (Figure 2C and D). One week after i.m. vaccination,
significant increases in both p15 (2.3-fold) and p11 (3.3-fold)
specific responses were observed in MVA-Ag85A IMX313
vaccinated mice compared to MVA-Ag85A controls (Figure 2C),
with a similar enhancement observed in intradermally (i.d.)
immunized mice (Figure 2D). MVA vaccines were subsequently
compared in a variety of prime-boost combinations to determine
the priming versus boosting capacity of the IMX313 fusion in two
separate strains of mice: Balb/c and C57BL/6. Mice received an
i.m. priming vaccination with either MVA-Ag85A or MVA-
Ag85A IMX313 followed two weeks later with either 10
6 PFU of
MVA-Ag85A or MVA-Ag85A IMX313 delivered via the i.m.
route (Figure 2E and F). Two weeks after the second immuniza-
tion, the highest response in either strain of mice was observed
after homologous immunization with MVA-Ag85A IMX313
(Figure 2E and 2F). In Balb/c mice, a 2.2-fold increase in the
mean CD4
+ T cell response (95% CI 1.82–2.60) and 3.3-fold
increase in the mean CD8
+ T cell response (95% CI 2.52–4.00)
was observed when compared to mice homologously vaccinated
with MVA-Ag85A (Figure 2E). In summary, fusion of IMX313 to
Figure 1. Schematic representation of Ag85A and Ag85A
IMX313 protein constructs. (A). tPA=signal peptide from human
tissue plasminogen activator (30 aa); Ag85A(1–323)=residues 1 to 323
of M. tuberculosis antigen 85A; PK=SV5-PK epitope tag (9 aa);
IMX313=hybrid chicken oligomerization domain of C4bp (55 aa). C
indicates cysteine residue. Western blots labeled with anti-Ag85A
polyclonal antibody (B and D) or anti-IMX313 polyclonal antibody (C)o f
non-reducing (B and C) and reducing (D) SDS-PAGE gels of BHK cell
lysates 24 h post infection with the indicated viruses. Arrowheads
indicate disulphide-linked dimers formed by Ag85A and asterisks
indicate higher molecular weight disulphide-linked multimers, presum-
ably heptamers, formed by Ag85A IMX313.
doi:10.1371/journal.pone.0033555.g001
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vaccine delivery systems and in two strains of mice.
Fusion of antigen 85A to IMX313 enhances the immune
response in rhesus macaques
While mice have proved to be excellent indicators of
immunogenicity, the ability to predict efficacy from murine
tuberculosis models has often been disappointing [19] and larger
animals may be better predictors of human immunogenicity and
efficacy. As the primary focus of this study was to test the capacity
of IMX313 to increase T cell responses, we performed further
immunological assessments in non-human primates.
Rhesus macaques were immunized with 10
8 PFU of MVA-
Ag85A or MVA-Ag85A IMX313 at weeks 0 and 6, and the
response to antigen 85A was measured by IFN-c ELISpot 1 week
after vaccination, then every 2 weeks using a single pool of 66
Figure 2. Screening of DNA and MVA vaccines in mice. A & B) Balb/c mice were immunized i.m. at weeks 0 and 2 with 50 mg of pSG2-Ag85A
or pSG2-Ag85A IMX313. IFN-c ELISpot was used to measure the response to the p15 and p11 peptides (together) in the blood 12 days after each
vaccination (A) of each individual peptide in the spleen 14 days after the final vaccination (B). C & D) In two separate experiments, Balb/c mice were
immunized i.m. (C) or i.d. (D) with 10
6 PFU of MVA-Ag85A or MVA-Ag85A IMX313 and the response to p15 and p11 measured in the spleen of all
animals 7 days later. E & F) Balb/c (E) or C57BL/6 (F) mice were immunized i.m. with 10
6 PFU of MVA-Ag85A or of MVA-Ag85A IMX313 at weeks 0 and
2. Intracellular cytokine staining was performed on spleen samples taken 2 weeks after the final vaccination. Graphs represent the frequency of IFN-c
producing CD4
+ (left) or CD8
+ (right) T cells in response to a single pool containing all Ag85A peptides. For all graphs, the bar represents the mean
per group with each individual animal displayed as a single point. Data were analyzed with a 2-way analysis of variance; fusion to IMX313 was shown
to induce a significant effect in all data sets (A p,0.001, B p=0.0298, C p,0.001, D p=0.0002, E p=0.0017, F p=0.0415). No interaction between
prime/boost or CD4
+/CD8
+ T cell responses were observed in any experiment and when analyzed with a post-hoc Bonferroni test; the asterisks
denote the level of statistical significance (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0033555.g002
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The peak of the antigen 85A-specific responses was observed 1
week after each vaccination (Figure 3A and B) consistent with
previous data in mice and humans [20]. At multiple timepoints,
higher antigen 85A responses were observed in the group of
animals vaccinated with the MVA-Ag85A IMX313 when
compared to those vaccinated with MVA-Ag85A (Figure 3). We
conducted two separate analyses to determine if there was a
statistically significant effect of IMX313. Firstly, without making
distributional assumptions, we noted that over the weeks 1–13, the
total number of Ag85A IFN-c secreting cells in the MVA-Ag85A
IMX313 group was greater than those in the MVA-Ag85A control
group (Kruskal-Wallis test, p=0.02), this was also true with single
peptide pools A, B, C, D, and G (p=0.05, 0.07, 0.05, 0.08, 0.02,
respectively, Figure S1). In a second approach, we constructed a
parametric model of the responses to the seven individual peptide
pools to derive an estimate of IMX313 induced effect of 1.8-fold
(95% CI 1.31–2.41). Despite the increased variance in immune
responses to Ag85A detected in non-human primates, the
magnitude of the increase was similar in the two species.
To measure whether vaccination with IMX313 induced cross-
reactive T cells to C4bp, frozen PBMCs were thawed and the
response to 85A peptides, IMX313 peptides and hC4bp peptides
measured by IFN-c ELISpot. In agreement with the data from
freshly isolated PBMCs, a statistically significant increase in the
antigen 85A response was observed 1 week after the second
vaccination in MVA-Ag85A IMX313 animals compared to the
controls (Figure 3C left panel). Only 1 animal had a detectable T
cell response to IMX313 peptides (Figure 3C central panel) and
importantly no detectable response to human C4bp was observed
in any of the macaques (Figure 3C right panel). Antibodies to 85A,
IMX313 and human C4bp were also assessed but no detectable
responses above background to any of the antigens were observed
(data not shown).
In summary, consistent with the data observed in mice, fusion to
IMX313 resulted in an overall increase in the responses to the
antigen 85A induced by MVA vaccination and importantly did
not result in the induction of cross-reactive T cells to the
oligomerization domain of C4bp.
Fusion of antigen 85A to IMX313 does not alter the
quality of the immune response in mice and macaques
A number of recent studies have suggested that the quality of
the immune response, as determined by cytokine polyfunction-
ality, can have a substantial effect on the overall protective ability
of a vaccine regime [21,22]. While there is no clear correlate of
protection to TB, T cells have a protective effect [16,17,18] and
any second-generation TB vaccine should ideally augment the
level of both CD4
+ and CD8
+ T cell immunogenicity while
maintaining its overall quality.
We therefore investigated whether fusion to IMX313 altered the
quality of the immune response in terms of cytokine secretion and
differentiation into effector and memory T cells. In the MVA
prime-boost experiments described above (Figure 2E), splenocytes
were stimulated with a single pool of antigen 85A analyzed for the
intracellular production of IFN-c, IL-2, TNFa and simultaneously
stained for CD62L and CD127 to discriminate between the three
main population of T effector and memory cells [23,24]. In Balb/c
mice, CD4
+ T cells were shown to produce predominately all of
the three cytokines measured (IL-2, IFN-c and TNF-a: triple
positive cells) or IL-2 alone (Figure 4A) and homologous prime-
boost with MVA-Ag85A IMX313 was shown to induce the highest
frequency of both of these subsets when compared to the control
MVA-Ag85A vaccinated group (Figure 4A). This increase in
frequency did not come at a cost to other cytokine producing
subsets, as there was no change in the proportion of cytokine
producing cells that secreted either 1, 2 or all 3 cytokines
(Figure 4A pie-charts). CD8
+ T cells demonstrated a difference in
the cytokine profile compared to CD4
+ T cells, the predominant
cytokine producing population observed was CD8
+ T cells that
simultaneously produced IFN-c and TNF-a (double positive) or
IFN-c only (Figure 4B). An overall increase in the frequency of
IFN-c and TNF-a or IFN-c only producing CD8
+ T cells in
MVA-Ag85A IMX313 vaccinated mice did not alter the other
subsets, as equal proportions of cells producing 1, 2 or all 3
cytokines were observed between all groups of mice (Figure 4B pie-
charts). To analyze the differentiation of antigen-specific cells into
effector and memory T cell subsets, any cell producing at least one
cytokine (i.e. IFN-c or TNF-a or IL-2) was analyzed for the
expression of surface markers of CD127 and CD62L and
separated into CD127
+, CD62L
+ T central memory (Tcm) cells,
CD127
+, CD62L
2 T effector memory (Tem) cells or CD127
2,
CD62L
2 T effector (Teff) cells. A higher frequency of both CD4
+
Tem cells (Figure 4C) and CD8
+ Tem cells (Figure 4D) were
observed in MVA-Ag85A IMX313 vaccinated mice when
compared to MVA-Ag85A controls (Figure 4C). In all groups of
animals, around 90% of either CD4
+ or CD8
+ cytokine producing
T cells displayed a Tem phenotype, indicating that the fusion of
antigen 85A to IMX313 did not skew the distribution of measured
phenotypes.
A similar analysis of quantity versus quality was performed on
the non-human primate samples one week after the second MVA
vaccination. Frozen PBMCs were restimulated with a single pool
of antigen 85A peptides and cells analyzed for upregulation of
CD107 (a marker of degranulation) [25], intracellular production
of IFN-c, IL-2 and TNF-a and surface expression of CD95 and
CD28. The predominant CD4
+ T cell sub-population seen was
cells secreting TNF-a alone or in combination with IFN-c, IL-2 or
both (i.e. triple positive cells) (Figure 5A). Consistent with the data
in mice, MVA-Ag85A IMX313 vaccinated animals displayed an
overall increase in the frequency of these populations, but this did
not result in a change in the proportion of cells producing either 1,
2 or all 3 cytokines (Figure 5A pie-charts). Substantially lower
overall responses were observed in CD8
+ T cells (Figure 5B
graphs) and in the MVA-Ag85A IMX313 group, two strong
responders drove a shift towards a higher proportion of cells
producing all three cytokines and upregulating CD107a (Figure 5B
graphs). Importantly, the weaker responding animals in this group
displayed an identical proportional distribution to animals
vaccinated with MVA-Ag85A (Figure 5B pie-charts), suggesting
it is the overall size of the immune response and not an effect of
IMX313 that was driving an increase in CD8
+ T cell multi-
functionality. At the same time, any cell producing one or more
cytokines or CD107a was analyzed for expression of CD28 and
CD95 and further subdivided into CD28
+CD95
+ Tcm,
CD28
2CD95
+ Tem or CD28
+CD95
2 Teff cells [26,27,28]. One
week after a second vaccination with MVA, Tcm was the
predominant phenotype of antigen 85A specific CD4
+ T cells
observed (Figure 4C), consistent with previous data from
macaques [28]. An increase in the total frequency of CD4
+ Tcm
cells was seen in MVA-Ag85A IMX313 vaccinated animals
(Figure 5C left panel) yet this did not alter the differentiation of
cells into either Teff,T em or Tcm (Figure 5C middle panel). This
trend was less clearly observed for CD8
+ T cells due to the overall
lower responses (Figure 5D). However it is clear that strong CD8
+
T cell responding animals displayed a predominantly Tem
phenotype (Figure 5D right panel), while weaker responders
displayed equal distribution of cells into Teff,T em and Tcm cells,
Antigen Multimerization Enhances T Cell Responses
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from both mice and macaques demonstrate that fusion to IMX313
increased the frequency of antigen 85A specific cells without
altering the overall quality of the immune response generated in
terms of multi-functionality or differentiation into effector or
memory T cell subsets.
IMX313 has a very early effect on the immune response
An increase in antigen persistence, stability and/or uptake as a result
of multimerization or binding of IMX313 to a specific (in vivo)t a r g e t
receptor, are all conceivable mechanism of IMX313 induced immune
response enhancement. As all of these mechanisms could have an early
effect on the immune response, we characterized the in vivo response as
early as 3 days after MVA vaccination.
We then characterized the cellular composition of the lymph
node to determine whether IMX313 was mediating an effect on
APC recruitment and activation. Three days after MVA
vaccination, draining auricular lymph nodes were harvested to
investigate the frequency and number of CD4
+ T cells, CD8
+ T
cells, B cells, macrophages and more specifically a number of
Figure 3. Macaque IFN-c ELISpot responses. Male rhesus macaques were immunized i.d. at weeks 0 and 6 with either 10
8 PFU MVA-Ag85A or
MVA-Ag85A IMX313 and the response to antigen 85A measured in the blood by IFN-c ELISpot before vaccination (pre) and every 2 weeks from week
1 onwards. Graphs represent the response of each individual animal to a single pool containing all antigen 85A peptides (A) or the sum of 7 separate
peptide pools (B). C) Graphs represent the ELISpot responses of frozen PBMCs to a pool of antigen 85A peptides, a pool containing IMX313 peptides
and a pool containing hC4bp peptides, pre-vaccination and at week 1 or week 7 post-vaccination. Bars represent the median group response with
each animal displayed as a single point. Data was analyzed with a 2-way analysis of variance with a post-hoc Bonferroni test; the asterisks denote the
level of statistical significance (*p,0.05).
doi:10.1371/journal.pone.0033555.g003
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timepoint, there were significant changes in the composition of
draining lymph nodes in terms of the frequency of each cell
population (Figure S2B), but all lymphocyte populations where
shown to increase in total number (Figure S2C). The most
dramatic increase was observed for CD11c
+ DCs (Figure S2C)
primarily due to an influx in CD11b
+ MHC II
intermediate (
int) DCs
(Figure S2D), although other DC subsets did also increase in
number (Figure S2D, E). Recruitment of these DCs was antigen
85A independent, as a similar frequency and number were present
after vaccination with an irrelevant MVA (Figure S2F, G).
IMX313 did not however alter the activation state of CD11b
+
MHC II
int DCs, as no change in CD80 (Figure S2H) or MHC
class II expression (Figure S2I) was observed.
While we observed no prolonged antigen 85A persistence or
specific effect of IMX313 on lymph node cell populations, these
Figure 4. Quality of the antigen 85A response in Balb/c mice. A & B) Pie charts represent the proportion of CD4
+ T cells (A) or CD8
+ T cells (B)
secreting either 1, 2, or all 3 cytokines measured, while the graphs represent the percentage of each cytokine subset as a frequency of all CD4
+ or
CD8
+ T cells. C & D) Any CD4
+ (C) or CD8
+ (D) T cell secreting either IFN-c, TNF-a or IL-2 was further subdivided into either CD62L
2,CD127
2 Teff,
CD62L
2,CD127
+ Tem or CD62L
+, CD127
+ Tcm cells and plotted as a percentage of the total CD4
+ or CD8
+ T cell population (left panel) or as a
percentage of all cytokine positive cells (right panels). Bars represent the group mean response with each individual animal displayed as a single
point. Data were analyzed with a 2-way analysis of variance; fusion to IMX313 was shown to induce a significant effect only for the absolute
frequency of cytokine
+ CD8
+ T cells (B graph p=0.0145) and absolute frequency of memory subset CD4
+ T cells (C left panel p=0.0337). No
interaction between prime-boost combination or cytokine subset was observed in any experiment and when analyzed with a post-hoc Bonferroni
test; the asterisks denote the level of statistical significance (*p,0.05).
doi:10.1371/journal.pone.0033555.g004
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antigen dose, which could also be affected by stability and uptake
of antigen 85A. As changes in T cell frequencies and activation
marker expression has been observed in vivo with alterations in
antigen dose [29,30], we investigated both of these factors as a
potential surrogate marker of in vivo antigen dose. Balb/c mice
were immunized with MVA-Ag85A or MVA-85A IMX313 and
draining lymph nodes harvested 3 days later. Using intracellular
IFN-c staining to identify antigen 85A-specific cells, we observed
an early increase (2-fold) in the frequency of both CD4
+ (Figure 6A)
Figure 5. Quality of the response to antigen 85A in rhesus macaques 1 week after a homologous MVA-Ag85A boost. A & B) Graphs
represent the frequency of each cytokine producing subset as a percentage of all CD4
+ (A) or CD8
+ (B) T cells, while the pie charts represent the
proportion of cytokine producing cells positive for 1, 2, 3 or all 4 markers. C & D) Any cell positive for either CD107a, IFN-c, TNF-a or IL-2 was further
subdivided into a CD28
+CD95
2 Teff, CD28
2CD95
2 Tem or CD28
+CD95
+ Tcm cell. Graphs on the left represent the absolute frequency of each memory
population relative to the total number of CD4
+ (C) or CD8
+ (D) T cells, centre graphs represent the percentage of each population relative to
cytokine producing cells, and graphs on the right represent total percentage of cytokine
+ cells compared to the percentage of each individual T cell
population. For each graph the bars represent the median group response, with each animal displayed as a single point. Data were analyzed with a 2-
way analysis of variance, no statistical difference between the two groups of vaccinated animals was observed.
doi:10.1371/journal.pone.0033555.g005
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+ (Figure 6B) T cells in MVA-Ag85A IMX313 vaccinated
mice compared to MVA-Ag85A controls. Despite this increase, we
observed no statistically significant changes in the levels of a
number of T cell activation markers investigated (Figure S3),
demonstrating once again that IMX313 was not skewing the
induction of the T cell responses in any particular way.
In summary, while this in vivo characterization did not suggest a
specific receptor for IMX313, we observed an increase in antigen
specific cells as early as three days after MVA vaccination, showing
that the effect of IMX313 occurs very early in the immune
response.
Discussion
In this study we have used the M. tuberculosis antigen 85A as a
model to demonstrate the potent cross-species adjuvant effect of
IMX313. Straightforward procedures were used to incorporate
this adjuvant into two vectored vaccine systems, and an immune-
potentiating effect was subsequently demonstrated in both mice
and non-human primates. In both animal models the fusion of
antigen 85A to IMX313 resulted in an augmentation of the
response without skewing it towards a particular cytokine-
producing population as has been observed with some traditional
adjuvants [31,32].
Our detailed in vivo characterization of the response three days
after vaccination did not reveal a specific activation effect of
IMX313. However at this timepoint, we observed a significant
increase in the frequency of antigen 85A specific CD4
+ and CD8
+
T cells (Figure 6). The two-fold increase at day 3 was equivalent to
the fold increase observed at day 7, and since this fold increase was
maintained over the course of the response, it would suggest that
IMX313 does not affect the rate of T cell division. Therefore the
increase in antigen specific cells occurs as a result of an early event
in T cell activation, most likely an increase in the effective in vivo
antigen dose, i.e. amount of antigen presented. This is supported
by our data showing no shift in the kinetics or quality of the 85A
immune response by fusion to IMX313. In addition, the consistent
effect of IMX313 in DNA and MVA and via different vaccination
routes would support a mechanism that relies on an early antigenic
effect, as opposed to a specific recruitment of cells or receptors that
may not be accessed by different vectors or vaccination routes.
It is not clear how multimerization enhances the effective in vivo
antigen dose. Fusion to C4bp was originally proposed to increase
the serum half-life of proteins and their immunogenicity [6], but
multimerization may itself result in an increase the uptake of
antigen 85A by APCs due to increased avidity. Antigen multi-
merization may also lead to prolonged antigen presentation by
making antigen 85A more difficult to process [33]. In an elegant
study, Delmarre et al demonstrated that by increasing the
lysosomal susceptibility, both T and B cell immunogenicity was
reduced in vivo. Bins et al [34]# subsequently demonstrated that
increasing in vivo luciferase stability resulted in increased levels of T
cell immunogenicity induced by DNA vaccination without altering
the kinetics of the immune response, supporting the data observed
in this study. Fusion of antigen 85A to IMX313 may either
increase serum half-life, improve antigen uptake, prolong antigen
processing or all of the above and further experiments are
underway to try and address some of these possibilities.
While many molecular adjuvants fall victim to species
differences in signaling and activation pathways, multimerization
takes advantage of the immune system’s natural response to an
increase in effective in vivo antigen dose, so that its effect is
consistently observed through different vaccine platforms and in
two very different animals species. Thus multimerization as an
adjuvant platform should have broad applicability to a variety of
diseases where cell-mediated immunity plays an important role,
e.g. malaria, TB, HIV and influenza. In summary, this relatively
simple technology of antigen multimerization could be useful in a
wide range of vaccine programs, both veterinary and human, as
well as for some non-communicable diseases.
Materials and Methods
Plasmids, viruses and cells
A 229 bp DNA fragment encoding the IMX313 domain was PCR
amplified from the plasmid pIMX313 [6] using the oligonucleotides 59-
GAAGCCCGACCTGCAACGTGGATCCAAGAAGCAAGGT-
GATGCTGATG-39 and 59-AGGGCCCTCTAGATGCATGCTC-
GAGCGGCCGCTTATTACTCCTTGCTCAGTCCTTGC-
39 and inserted into the DNA vaccine vector pSG2-Ag85A [35] using
site-directed mutagenesis [36]#. This replaced the 9 amino acid PK
tag at the C-terminus of antigen 85A protein with the 55 amino acid
IMX313 domain. Ag85A IMX313 was conventionally subcloned into
the poxvirus shuttle vector pMVA-GFP-TD which places it under the
control of the vaccinia virus p7.5 promoter and provides flanks for
recombination at the TK locus of MVA. Markerless recombinant
viruses were isolated following transfection of this plasmid into infected
primary chick embryo fibroblasts (CEFs) (Day 9 of gestation) (Institute
for Animal Health) by transient dominant selection with GFP. For
immunizations, viruses were amplified in CEFs, purified over sucrose
cushions, and titered twice in duplicate by plaque assay according to
standard methods. Virus identity and purity was confirmed by PCR.
Ethics Statement
Mice were used in accordance with the UK Animals (Scientific
Procedures) Act under project license number 30/2414 granted by
the UK Home Office.
Male rhesus macaques (Macaca mulatta) aged between 2 K to 6
years were maintained and used at the Institute of Neurobiology
and Molecular Medicine, National Research Council of Italy, in
accordance with approval granted by the ethics committee of the
Italian Ministry of Health (Decree by low nu: 2007 114 B and nu
2007 115 C). The animal care routine and experimental
procedures were in compliance with national and international
laws and policies (EEC Council Directive 86/609; Italian
Figure 6. T cell responses in the draining auricular draining
lymph node three days after vaccination with 10
6 PFU MVA-
Ag85A. Graphs represent the frequency of IFN-c
+ CD4
+ T cells (A)o r
CD8
+ T cells (B) after 6 hours of restimulation with the total antigen 85A
peptide pool and staining for a variety of surface activation markers
(S4). Data were log transformed and analyzed with a 2-way analysis of
variance; a significant effect of IMX313 fusion was only observed for the
frequency of antigen 85A specific cells p=0.0101 but not for any
surface marker (Figure S3).
doi:10.1371/journal.pone.0033555.g006
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taken to ameliorate suffering in accordance with the recommen-
dations of the Weatherall report, ‘‘The use of non-human primates
in research.’’ To minimize distress and suffering related to
vaccination or blood withdrawal, animals were anesthetized by
i.m. injection of 10 mg/kg ketamine hydrochloride for all
procedures and no animals were sacrificed at the end of the
experiment.
Animals and Immunizations
Female Balb/c or C57BL/6 mice of 6 weeks of age or older
(Harlan, UK) were immunized i.m. in the musculus tibialis or
intradermally (i.d.) in the ear with a total volume of 50 mlo f
vaccine diluted in PBS. Mice received either 50 mg of DNA or 10
6
PFU of MVA per vaccination.
Rhesus Macaques were assigned into each group to ensure
homogeneous distribution of age and body weight. The control
group (MVA-Ag85A) included a total of 4 animals with an average
weight of 5 kg (range 3.9–7.5 kg) and age of 4 years (range 2.8–
5.9); the test group (MVA-Ag85A IMX313) included 5 animals
with an average weight of 4.98 kg (range 4–7.55) and average age
of 4 years (range 3.4–6). Animals received two intradermal
immunizations, at weeks 0 and 6, with of 10
8 PFU of MVA, with
arms switched between vaccinations. Blood samples were kept at
room temperature and shipped overnight to Oxford where all
processing and assays were performed.
Western Blots
Monolayers of BHK-21 cells (European Collection of Cell
Cultures) were infected for 24 hours with MVA-Ag85A, MVA-
Ag85A IMX313 or an unrelated recombinant MVA at 4 PFU per
cell. Cells were washed in PBS and harvested into non-reducing
Laemmli’s sample buffer. After addition of ß-mercaptoethanol to
half of each sample, the lysates were processed for SDS-PAGE and
Western blotting by standard methods. Lanes were loaded with
volumes of lysate corresponding to approximately 10
5 infected
cells. Blots were labeled with chicken anti-85A (AbCam) or a
hyperimmune serum from rabbits immunized with IMX313
protein, followed by alkaline phosphatase conjugated secondary
antibodies (Jackson) and colorimetric visualization.
Peptides
Murine cells were stimulated with the CD8 epitope p11
WYDQSGLSV (aa 103–111), CD4 epitope p15 TFLTSELPGWL-
QANRHVKPT (aa 142–161) (ProImmune, UK) from Ag85A
(GenBank accession no. CAA17868) [37,38,39,40] or a single pool
containing all 66 antigen 85A peptides (20mer peptides overlapping
by 10) (Peptide Protein Research, UK). Fresh and frozen macaque
PBMCs were stimulated with the single pool of antigen 85A
peptides, 7 pools spanning antigen 85A (Table S1), a single pool of
IMX313 peptides (Table S2) (20mers overlapping by 10) (ProIm-
mune) or a single pool of the oligomerization domain of human
C4bp (Table S2) (20mers overlapping by 10) (ProImmune) at a final
concentration of 2 mg/ml.
ELISpots
Murine spleens or peripheral blood samples were treated with
ACK lysis buffer to remove RBCs prior to stimulation with the
relevant peptides (final concentration of 2 mg/ml) on IPVH-
membrane plates (Millipore) coated with 5 mg/ml anti-mouse
IFN-c (AN18). Macaque PBMCs were isolated over a lymphoprep
gradient (Sigma) while frozen PBMCs were thawed and rested
overnight in media containing 10 U/ml Benzonase (Sigma).
250 000 PBMCs per well were stimulated with relevant peptides
at a final concentration of 2 mg/ml on IPVH-membranes coated
with 15 mg/ml anti-human IFN-c (GZ4).
After 18–20 hours of stimulation, IFN-c spot forming cells
(SFC) were detected by staining membranes with either anti-
mouse IFN-c biotin (1 mg/ml) (R46A2) or anti-human IFN-c (7-
B6-1) followed by streptavidin-Alkaline Phosphatase (1 mg/ml) and
development with AP conjugate substrate kit (BioRad, UK).
Intracellular cytokine staining
Murine splenocytes were stimulated for a total of 6 hours with a
single pool containing all antigen 85A peptides (2 mg/ml final
concentration) or media only (unstimulated control), with the
addition of Golgi-Plug (BD) (1 mg/ml) for the final 4 hours.
Following surface staining with CD4-APCAlexa780, CD8
PerCPCy5.5, CD62L-PECy7 and CD127 Pacific Blue, cells were
fixed with 4% paraformaldehyde and stained intracellularly with
TNF-a Alexa488, IL-2 PE and IFN-c Alexa647 diluted in Perm-
Wash buffer (BD).
Frozen macaque PBMCs were thawed and rested overnight in
media containing 10 U/ml Benzonase (Sigma). 2610
6 PBMCs
were restimulated for 6 hours in 96 well U-bottom plates (total
volume of 200 ml) with 1 mg/ml anti-human CD49d (9F10), 20 ml
anti-human CD28-APC (CD28.2) and 20 mlo fa n t i - h u m a n
CD107a-PECy5 (eBIOH4A3) in addition to 2 mg/ml antigen
85A peptide pool or DMSO (unstimulated control) with the
addition of Golgi-Plug (1 mg/ml) and Golgi-Stop (0.8 mg/ml) for
the final 4 hours. Cells were surface stained for CD95-biotin
(DX2) followed by strepavidin qDot 565, CD4 eFluro605
(OKT4), Live-Dead Violet (Invitrogen), CD14 eFluro 450
(61D3) and CD20 eFluro 450 (2H7). Cells were fixed with 4%
paraformaldehyde and stained intracellularly for TNF-a FITC
(MAb11), IL-2 PE (MQ1-17H12), IFN-c PECy7 (4S.B3), CD3
Alexa700 (SP34-2) and CD8-APC Alexa780 (RPA-T8) diluted in
Perm-Wash.
Sample acquisition was performed on a LSR II and data
analyzed in FlowJo (TreeStar), Pestle v1.6 and Spice v 4.3 [41]
with all final figures made in Canvas X (ACD Systems).
Statistical methods
All graphs and statistical analysis were created in Prism v5.0c
(Graphpad), data were log transformed and a one-way or two-way
analysis of variance performed; figure legends denote the test
performed for each experiment. Where IMX313 was shown to
induce a significant effect, a Kruskal Wallace (one-way ANOVA)
or Bonferroni test (two-way ANOVA) was performed and p values
stated in the figure legend.
For analysis of macaque peptide pool data, Kruskal-Wallis tests
were used to compare the responses from animals at baseline
(pre-immunization) with those at all timepoints after immuniza-
tion. Parametric models estimating the effect of IMX313 modeled
log(number of IFN-c secreting cells, detected by ELISpot) as an
outcome variable, because of the approximate log-normal
distribution of ELISpot counts in these animals (not shown).
Conditions with no spots were scored as having 1 spot, which is
the limit of detection of the assay. Modeling of Log(ELISPO-
T),Effect of IMX313+effect of Timepoint+effect of peptide pool allowed
estimation of an overall effect of IMX313. Assumptions include (i)
the responses to the peptide pools are independent, (ii) the effect
IMX313 is similar over all peptide pools, (iii) the effect of
IMX313 is similar over timepoints, (iv) effect of IMX313 is
similar across animals. Analyses used R2.1.1 for Windows and
Graph Pad Prism software.
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Figure S1 Immune responses to MVA-Ag85A and MVA-
Ag85A IMX313 in macaques. Shown are individual responses
to seven peptide pools (A–G) and a 66 peptide pool (‘Pool’) in five
animals receiving MVA-Ag85A IMX313 (+) and four animals
receiving MVA-Ag85A control (o) before vaccination (shown at
t=0), and at 1,3,5,7,9 and 13 weeks after the first vaccination (at
t=0, dashed vertical line); a second vaccination was given at week
6 (dashed vertical line). Geometric means are shown at each time
point, joined by a solid line (Ag85A) or a dashed line (Ag85A
IMX313). Conditions with no detectable response are shown as
having 1 spot (see Methods). p values test the hypothesis that
responses in the Ag85A-IMX313 post vaccination exceed those in
the Ag85A group (Krustal-Wallis test).
(TIF)
Figure S2 IMX313 does not induce activation of APCs.
Balb/c mice were immunized i.d. with 10
6 PFU MVA-Ag85A
(circles) or MVA-Ag85A IMX313 (squares) or unvaccinated
(diamonds) and draining auricular lymph nodes harvested 3 days
later for analysis by flow cytometry. Organs were diced into small
pieces and digested at room temperature for 30 minutes in PBS
containing 0.3 mg/ml collagenase-dispase (Roche) and 0.02 mg/
ml DNAse. For initial characterization of MVA vaccinated mice,
LNs were surface stained for CD80-FITC, CD11c PE, CD8
PerCPCy5.5, B220-PECy7, F4/80 Pacific Blue, CD103-biotin,
streptavidin qDot 565, CD4-qDot 655, CD11b Alexa-700, MHC
Class II APC-Alexa780 and Live-Dead Aqua prior to fixation and
intracellular staining with CD207-APC (eBioscience) in perm-
wash buffer. A) FACS plots demonstrate the gating strategy to
classify the population of CD11c
+B220
2CD11b
+MHC II
int DCs
relative to plasmacytoid DCs (pDCs), lymph node (LN) resident
DCs, or skin migrating DCs isolated from the draining auricular
nodes (top panel) or non-draining inguinal and popliteal nodes
(bottom panel) three days after id vaccination. CD11b
+MHC II
int
DCs were overlayed over the population of LN resident DCs to
investigate expression of CD4 and CD8, or overlayed over the
population of skin migrating DCs to investigate the expression of
CD103 and CD207. Histograms represent the expression of either
F4/80 (left) or CD80 (right) on LN resident (grey filled line), skin
migrating (black dashed line) or CD11b
+MHC II
int (black bold
line) DCs. Graphs represent the percentage of live cells (B) or total
number (C) of B cells (B220
+CD11c
2), CD4 (CD4
+CD8
2), CD8
(CD8
+CD4
2), DCs (CD11c
+) and CD11c
2CD11b
+. CD11c
+
MHC II
+ cells were further subdivided into plasmacytoid DCs
(pDCs) (B220
+), CD11b
+ MHC II
int, LN resident (CD11b
2, MHC
II
int) or skin migrating (MHC II
hi) with graphs representing the
percentage (D) or total number of each population (E). In a
separate experiment, auricular LNs from Balb/c mice immunized
id with 10
6 PFU of either MVA-GFP (triangle), MVA-Ag85A
(circles), MVA-Ag85A IMX313 (square) or unvaccinated (diamonds)
were analyzed at day 3 days by flowcytometry. Digested lymphnodes
were surface stained for CD80-FITC, CD11c-PE, CD8-
PerCPCy5.5, B220-PeCy7, CD4-qDot650, CD11b-Alexa700,
MHC Class II APC with the addition of DAPI prior to acquisition
of samples on the LSR II. Graphs represent the percentage (F)a n d
total number (G) of CD11b
+MHC
int cells or surface expression level
of CD80 (H) or MHC Class II fluorescence (I)o nC D 1 1 b
+MHC II
int
cells. In all graphs, bars represent the mean per group with each
individual animal displayed as a single point.
(TIF)
Figure S3 Expression of activation markers on IFN-g
+
CD4
+ or CD8
+ T cells 3 days after immunization. Balb/c
mice were vaccinated id with 10
6 PFU MVA85A or MVA85A-
IMX313 and the draining auricular lymph node harvested 3 days
later. After 6 hours of restimulation with the total 85A peptide
pool, cells were surface stained with CD69-FITC, CD44-PE,
CD8-PerCPCy5.5, CD62L-PECy7, CD127 Pacific Blue, CD122-
bi followed by streptavidin dQot565 (Invitrogen), CD4-eFluro 650
and CD25-Alexa700 prior to fixation and intracellular staining for
IFN-c Alexa647. Cells were subdivided into either CD4
+ T cells
(A) or CD8
+ T cells (B) prior to analysis of IFN-c and surface
marker expression. Data was analyzed with a two-way analysis of
variance and no statistically significant difference was observed for
any marker investigated.
(TIF)
Table S1 Ag85A peptide pools. The table lists the separation
of the 66 individual 20 mer peptide (overlapping by 10) spanning
the length of Ag85A into the 7 peptide pools labelled A to G.
(DOCX)
Table S2 Amino acid sequences of C4bp oligomeriza-
tion domains. Using a Clustal V Method of alignment
(MegAlign, DNASTAR Lasergene software), bold letters repre-
sents homologous amino acids between chicken, IMX313 and
human protein sequences. Grey letters represent the amino acid
changes between human and the predicted rhesus macaque
sequence (accession no. XP_002801994). Italic letters represent
the major sequence change made to chicken version 1 in
construction of IMX313, to reduce sequence homology to the
human sequence.
(DOCX)
Acknowledgments
We thank G. Perretta, A. Taglioni, C. Williams and V. Clark for their
animal husbandry; A. Pathan, H. Fletcher and H. McShane for donation
of 85A peptide pools; A. Folgori, T. Lambe, A. Reyes-Sandoval, A. Worth
and the Jenner Institute Vector Core facility for assistance; and H.
McShane for discussions. SCG, SJD and AVSH are Jenner Institute
Investigators.
Author Contributions
Conceived and designed the experiments: AJS FH MGC MB AVSH.
Performed the experiments: AJS JDH MGC CSR JF KCS. Analyzed the
data: AJS JDH MGC DHW. Contributed reagents/materials/analysis
tools: FH SJD SCG. Wrote the paper: AJS FH MGC AVSH.
References
1. Draper SJ, Heeney JL (2010) Viruses as vaccine vectors for infectious diseases
and cancer. Nat Rev Microbiol 8: 62–73.
2. Hill AV (2006) Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat
Rev Immunol 6: 21–32.
3. Engel J, Kammerer RA (2000) What are oligomerization domains good for?
Matrix Biol 19: 283–288.
4. Chambers RS, Johnston SA (2003) High-level generation of polyclonal
antibodies by genetic immunization. Nat Biotechnol 21: 1088–1092.
5. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, et al. (2008)
Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14:
819–821.
6. Ogun SA, Dumon-Seignovert L, Marchand JB, Holder AA, Hill F (2008) The
oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and
the fusion protein comprised of the 19-kilodalton merozoite surface protein 1
fused with the murine C4bp domain protects mice against malaria. Infect
Immun 76: 3817–3823.
Antigen Multimerization Enhances T Cell Responses
PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e335557. Kask L, Hillarp A, Ramesh B, Dahlback B, Blom AM (2002) Structural
requirements for the intracellular subunit polymerization of the complement
inhibitor C4b-binding protein. Biochemistry 41: 9349–9357.
8. Christiansen D, Devaux P, Reveil B, Evlashev A, Horvat B, et al. (2000)
Octamerization enables soluble CD46 receptor to neutralize measles virus in
vitro and in vivo. J Virol 74: 4672–4678.
9. Shinya E, Dervillez X, Edwards-Levy F, Duret V, Brisson E, et al. (1999) In-vivo
delivery of therapeutic proteins by genetically-modified cells: comparison of
organoids and human serum albumin alginate-coated beads. Biomed Pharmac-
other 53: 471–483.
10. Oudin S, Libyh MT, Goossens D, Dervillez X, Philbert F, et al. (2000) A soluble
recombinant multimeric anti-Rh(D) single-chain Fv/CR1 molecule restores the
immune complex binding ability of CR1-deficient erythrocytes. J Immunol 164:
1505–1513.
11. Libyh MT, Goossens D, Oudin S, Gupta N, Dervillez X, et al. (1997) A
recombinant human scFv anti-Rh(D) antibody with multiple valences using a C-
terminal fragment of C4-binding protein. Blood 90: 3978–3983.
12. Dervillez X, Huther A, Schuhmacher J, Griesinger C, Cohen JH, et al. (2006)
Stable expression of soluble therapeutic peptides in eukaryotic cells by
multimerisation: application to the HIV-1 fusion inhibitory peptide C46.
ChemMedChem 1: 330–339.
13. Ibanga HB, Brookes RH, Hill PC, Owiafe PK, Fletcher HA, et al. (2006) Early
clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic
countries: issues in study design. Lancet Infect Dis 6: 522–528.
14. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004)
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts
BCG-primed and naturally acquired antimycobacterial immunity in humans.
Nat Med 10: 1240–1244.
15. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, et al. (2008)
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy
adults in South Africa. J Infect Dis 198: 544–552.
16. Brookes RH, Pathan AA, McShane H, Hensmann M, Price DA, et al. (2003)
CD8+ T cell-mediated suppression of intracellular Mycobacterium tuberculosis
growth in activated human macrophages. Eur J Immunol 33: 3293–3302.
17. Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, et al. (1999) Mice
deficient in CD4 T cells have only transiently diminished levels of IFN-gamma,
yet succumb to tuberculosis. J Immunol 162: 5407–5416.
18. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P (2000)
Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T
cells. Eur J Immunol 30: 3689–3698.
19. Williams A, Hall Y, Orme IM (2009) Evaluation of new vaccines for tuberculosis
in the guinea pig model. Tuberculosis (Edinb) 89: 389–397.
20. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, et al.
(2005) Boosting BCG with MVA85A: the first candidate subunit vaccine for
tuberculosis in clinical trials. Tuberculosis (Edinb) 85: 47–52.
21. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007)
Multifunctional TH1 cells define a correlate of vaccine-mediated protection
against Leishmania major. Nat Med 13: 843–850.
22. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and
protection: implications for vaccine design. Nat Rev Immunol 8: 247–258.
23. Huster KM, Koffler M, Stemberger C, Schiemann M, Wagner H, et al. (2006)
Unidirectional development of CD8+ central memory T cells into protective
Listeria-specific effector memory T cells. Eur J Immunol 36: 1453–1464.
24. Bachmann MF, Wolint P, Schwarz K, Jager P, Oxenius A (2005) Functional
properties and lineage relationship of CD8+ T cell subsets identified by
expression of IL-7 receptor alpha and CD62L. J Immunol 175: 4686–4696.
25. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003)
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow
cytometric assay for degranulation. J Immunol Methods 281: 65–78.
26. Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, et al. (2008) Magnitude
and phenotype of cellular immune responses elicited by recombinant adenovirus
vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 82:
4844–4852.
27. Pitcher CJ, Hagen SI, Walker JM, Lum R, Mitchell BL, et al. (2002)
Development and homeostasis of T cell memory in rhesus macaque. J Immunol
168: 29–43.
28. Liu J, O’Brien KL, Lynch DM, Simmons NL, La Porte A, et al. (2009) Immune
control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature
457: 87–91.
29. Fazekas de St Groth B, Smith AL, Higgins CA (2004) T cell activation: in vivo
veritas. Immunol Cell Biol 82: 260–268.
30. Smith AL, Wikstrom ME, Fazekas de St Groth B (2000) Visualizing T cell
competition for peptide/MHC complexes: a specific mechanism to minimize the
effect of precursor frequency. Immunity 13: 783–794.
31. Grun JL, Maurer PH (1989) Different T helper cell subsets elicited in mice
utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in
proliferative responses. Cell Immunol 121: 134–145.
32. Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA (2001) The Common
vaccine adjuvant aluminum hydroxide up-regulates accessory properties of
human monocytes via an interleukin-4-dependent mechanism. Infect Immun
69: 1151–1159.
33. Delamarre L, Couture R, Mellman I, Trombetta ES (2006) Enhancing
immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med
203: 2049–2055.
34. Bins AD, Wolkers MC, van den Boom MD, Haanen JB, Schumacher TN (2007)
In vivo antigen stability affects DNA vaccine immunogenicity. J Immunol 179:
2126–2133.
35. Taracha EL, Bishop R, Musoke AJ, Hill AV, Gilbert SC (2003) Heterologous
priming-boosting immunization of cattle with Mycobacterium tuberculosis 85A
induces antigen-specific T-cell responses. Infect Immun 71: 6906–6914.
36. Geiser M, Cebe R, Drewello D, Schmitz R (2001) Integration of PCR fragments
at any specific site within cloning vectors without the use of restriction enzymes
and DNA ligase. Biotechniques 31: 88–90, 92.
37. Denis O, Tanghe A, Palfliet K, Jurion F, van den Berg TP, et al. (1998)
Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates
a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by
Mycobacterium tuberculosis H37Rv infection. Infect Immun 66: 1527–1533.
38. McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AV (2002) Protective
immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed
with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. Infect Immun
70: 1623–1626.
39. D’Souza S, Rosseels V, Romano M, Tanghe A, Denis O, et al. (2003) Mapping
of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B,
and Ag85C from Mycobacterium tuberculosis. Infect Immun 71: 483–493.
40. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, et al.
(2003) Enhanced immunogenicity and protective efficacy against Mycobacteri-
um tuberculosis of bacille Calmette-Guerin vaccine using mucosal administra-
tion and boosting with a recombinant modified vaccinia virus Ankara.
J Immunol 171: 1602–1609.
41. Roederer M, Nozzi JL, Nason MC (2011) SPICE: exploration and analysis of
post-cytometric complex multivariate datasets. Cytometry A 79: 167–174.
Antigen Multimerization Enhances T Cell Responses
PLoS ONE | www.plosone.org 11 March 2012 | Volume 7 | Issue 3 | e33555